Organisation paid for research Program year 2023 Source: CMS Open Payments

Clinical Research Advantage, Inc.

Neither a doctor nor a teaching hospital

Research payments

$145,562

64 payments

Through program year 2023, Clinical Research Advantage, Inc. is reported as receiving $145,562 in research payments, across 64 payments.

By program year

3 rows
Year Kind Amount Payments
2023 Research $337 2
2020 Research $75,280 2
2019 Research $69,945 60

Breakdown

Who paid Research payments · program years 2019–2023
  1. Eisai Inc. $136,768 54 payments
  2. Teva Pharmaceuticals USA, Inc. $5,900 3 payments
  3. Merck Sharp & Dohme Corporation $2,294 6 payments
  4. Shionogi Inc $600 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder $112,417 28 payments
  2. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $22,696 24 payments
  3. Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine $5,900 3 payments
  4. A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella MMRV Vaccine Made with an Alternative Manufacturing Process AMP $1,957 4 payments
  5. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors $1,375 1 payment
  6. Study of S-033188 Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications CAPSTONE 2 $600 1 payment
  7. A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin MK-8835,PF-04971729 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin $337 2 payments
  8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia $280 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record